Cytokine: X

Aims & Scope

Cytokine: X is the open access companion journal of Cytokine and has the same aims and scope and peer-review process.

Cytokine: X offers authors with high-quality research who want to publish in a gold open access journal the opportunity to make their work immediately, permanently, and freely accessible.

Cytokine: X authors will pay an article publishing charge (APC), have a choice of license options, and retain copyright.

View Aims & Scope

---

Metrics & Ranking

SJR (SCImago Journal Rank)

Year	Value
2024	0.637

Quartile

Year	Value
2024	Q2

h-index

Year	Value
2024	14

Journal Rank

Year	Value
2024	9056

Journal Citation Indicator

Year	Value
2024	24

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Biochemistry, Genetics and Molecular Biology, Immunology and Microbiology and Medicine, designed to support cutting-edge academic discovery.

---

Licensing & Copyright

This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.

Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the ‘culprit lesion’ of ARDS onset? What is there besides Tocilizumab? SGP130Fc

  Citation: 150

  Authors: Giuseppe

• Macrophages as host, effector and immunoregulatory cells in leishmaniasis: Impact of tissue micro-environment and metabolism

  Citation: 78

  Authors: Christian

• Cross-platform comparison of highly sensitive immunoassay technologies for cytokine markers: Platform performance in post-traumatic stress disorder and Parkinson’s disease

  Citation: 38

  Authors: Heather C., Allison C., Lauren E., Nikolaos P., Magali, Andreas

• The challenges and molecular approaches surrounding interleukin-2-based therapeutics in cancer

  Citation: 26

  Authors: Anthony, Fiona

• An IL-6-IL-8 score derived from principal component analysis is predictive of adverse outcome in acute myocardial infarction

  Citation: 24

  Authors: Gisela A., Ana S., Kathryn E., Morgane M., Bijia, Scott A., Peter D.

• Cytokines frequently implicated in myeloproliferative neoplasms

  Citation: 21

  Authors: Yingying, Xuelan

• Unravelling the unsolved paradoxes of cytokine families in host resistance and susceptibility to Leishmania infection

  Citation: 21

  Authors: Bernard Ong'ondo, Raphael Taiwo, Frank, Ramona

• Exclusive inhibition of IL-6 trans-signaling by soluble gp130FlyRFc

  Citation: 21

  Authors: Anna F., Julia, Hendrik T., Matthias, Doreen M., Jürgen, Jens M.

• Cytokines and splenic remodelling during Leishmania donovani infection

  Citation: 18

  Authors: Marcela, Christian R., Paul M.

• Using CRISPR to enhance T cell effector function for therapeutic applications

  Citation: 16

  Authors: Julian J.

---